Biogen and its investors both want US appeals court to clarify class certification
In a rare – and possibly unique – turn of events, both pharmacy company Biogen and its shareholders have asked a federal ...
Buy Rating Justified by Biogen’s Strategic Positioning and Strong Financial Outlook
Mizuho Securities analyst Salim Syed has maintained their bullish stance on BIIB stock, giving a Buy rating on September 24. Salim Syed has ...
The Best Performing S&P 500 Stocks Over the Past 30 Years Might Surprise You
A performance analysis of the current constituents of the S&P 500 Index Over the Last 30 Years ending September 2024 ...
朝日新聞社3d
US approves Alzheimer’s drug that modestly slows disease
Last week, a congressional report found that FDA's approval of a similar Alzheimer's drug called Aduhelm — also from Biogen and Eisai — was “rife with irregularities,” including a number ...
pharmaphorum1d
Biogen finally publishes its phase 3 Aduhelm data
Aduhelm was ultimately approved by the FDA based on the reduction in amyloid beta plaques observed in patients treated with the drug, a surrogate marker that Biogen links to cognitive effects.
pharmaphorum1d
Biogen pulls EU application for Alzheimer's drug Aduhelm
Biogen has given up on seeking approval for its Alzheimer's disease therapy Aduhelm in the EU, saying that discussions with EU regulators had made it clear the current data for the drug is not ...
Yahoo Finance4d
Biogen Inc. (BIIB): Among the Best Bargain Stocks to Buy In October
In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other bargain stocks. September has historically been sluggish for stocks. However, with an ...